COMMUNIQUÉS West-GlobeNewswire

Aleafia Submits Application to List on NASDAQ
02/10/2018
Up-Listing to NASDAQ to Provide Greater Exposure to U.S. Investors TORONTO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. ( TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH ) (“ Aleafia “) or (the “Company“), one of Canada’s [...]
SeaSpine Announces Preliminary Results for Third Quarter 2018
02/10/2018
Increases 2018 Financial Outlook CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of [...]
Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant for Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease
02/10/2018
Pittsburgh, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , a clinical stage neuroscience company focused on synaptic health and restoration in Alzheimer’s disease and other neurodegenerative disorders [...]
CareDx Profiles AlloSeq Suite of NGS Products at ASHI
02/10/2018
Expands portfolio with three new kitted transplant products launching in 2019 Delivers new insights into the clinical Transplantome by incorporating HLA plus additional genes contributing to successful transplant [...]
Yield10 Bioscience Obtains Nonregulated Status for its Novel CRISPR-Cas9 Triple Gene Edited Camelina Plant Lines to Boost Seed Oil Content
02/10/2018
--USDA-APHIS Response Marks Clearance of Yield10’s First Triple Genome-edited Plant Lines --Favorable Response Accelerates Path to U.S. Field Trials in 2019 WOBURN, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Yield10 [...]
Arzeda and BP Sign Collaborative Joint Development Agreement
02/10/2018
SEATTLE and HOUSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Arzeda, The Protein Design Company™, and BP announced a collaboration to develop a process for producing a renewable chemical with broad applications. This [...]
VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018
02/10/2018
Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501 Oral presentation at IDWeek 2018 on Saturday, October 6 th , 2018, at 11:10 AM PDT CAMBRIDGE, Mass., Oct. 02 [...]
Arzeda Leverages Scalable Synthetic Biology Resources to Drive Computational Protein Design Platform
02/10/2018
Integration of Providers Demonstrates the Power of Bioeconomy SEATTLE and SAN FRANCISCO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Arzeda, the Protein Design Company™, Twist Bioscience Corporation, TeselaGen Biotechnology Inc. [...]
Biotricity Provides Fiscal 2018 Second Quarter Updates for Shareholders
02/10/2018
Biotricity Reports an Increased Traction in Both Market Expansion and Sales REDWOOD CITY, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Biotricity Inc. ( OTCQB : BTCY ), a medical diagnostic and consumer healthcare [...]
International Stem Cell Corporation Raised Funds Through a Private Placement at Premium to Market
02/10/2018
CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) ( www.internationalstemcell.com ) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company [...]
Imagin Medical Announces Changes to Its Board of Directors
02/10/2018
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) announced that Steven Chan has [...]
Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial of RX-3117 in Combination With Abraxane® in Patients Newly Diagnosed With Metastatic Pancreatic Cancer
02/10/2018
Combination of RX-3117 and Abraxane Appears Safe and Well-Tolerated When Administered at the Recommended Phase 2 Dose of RX-3117 and the Maximal Labeled Dose of Abraxane Preliminary Efficacy was Observed With One [...]
Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
02/10/2018
BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for [...]
Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma
02/10/2018
MADISON, Wis., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of [...]
Melinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam)
02/10/2018
Vabomere monotherapy was associated with increased clinical cure, decreased mortality, and was well tolerated compared to best available therapy (BAT) - Data used by CMS in decision to grant a new technology add-on [...]
Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
02/10/2018
SYDNEY, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune [...]
Major Cancer Journal Highlights Data From An Inovio-Sponsored Trial In Which A Patient Achieved Full Remission After Dosing With DNA Immunotherapy and Checkpoint Inhibitor
02/10/2018
Study results published in Clinical Cancer Research shows that DNA immunotherapy approach drove T cell infiltration in tumors PLYMOUTH MEETING, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ [...]
BioCorRx Provides BICX102 Grant Update
02/10/2018
ANAHEIM, CA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided [...]
Otonomy Announces OTIVIDEX™ Data Presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
02/10/2018
Positive Results from AVERTS-2 Phase 3 Clinical Trial will Support Submission for U.S. Registration and Provide Basis for Ongoing Additional Phase 3 Trial SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. ( [...]

Pages